Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.58 |
| ▸ | CTSK | P43235 | 6/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.53 |
| ▸ | PLG | P00747 | 1/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 5/20 | 0.51 |
| ▸ | CTSL | P07711 | 4/20 | 0.51 |
| ▸ | CTSB | P07858 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | XBP1 | P17861 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22144905 | 1.00 | SYK (0.58) | SYKCTSKCYP1A2TPSAB1PLG | |
| SCHEMBL20529479 | 1.00 | SYK (0.58) | SYKCTSKCYP1A2TPSAB1PLG | |
| SCHEMBL19836950 | 0.90 | SYK (0.55) | SYKCTSKCYP1A2CTSSCTSL | |
| SCHEMBL10626940 | 0.90 | SYK (0.55) | SYKCTSKCYP1A2CTSSCTSL | |
| SCHEMBL26259369 | 0.90 | CYP1A2 (0.58) | CTSKCYP1A2TPSAB1PLGPRSS1 | |
| SCHEMBL30645052 | 0.89 | CTSK (0.66) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL26292050 | 0.89 | CYP1A2 (0.57) | CTSKCYP1A2TPSAB1PLGPRSS1 | |
| SCHEMBL26292046 | 0.89 | CYP1A2 (0.57) | CTSKCYP1A2TPSAB1PLGPRSS1 | |
| SCHEMBL20529378 | 0.88 | CAPN1 (0.54) | SYKCTSKCYP1A2TPSAB1PLG | |
| SCHEMBL30387033 | 0.87 | SYK (0.63) | SYKCTSKCYP1A2TPSAB1PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2025-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | FCGR2A, FCGR3B, FCGR1A | SYK 182/4885CTSK 1875/4885CYP1A2 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.